alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 23,576–23,600 of 27,146 studies marked Peer-reviewed (page 944 of 1086) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Estimates of diagnosed dementia prevalence and incidence among diverse beneficiaries in Traditional Medicare and Medicare Advantage

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2023-12-01

Lower diagnosed dementia rates in MA compared to TM may exacerbate racial/ethnic disparities in diagnosed dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Racial disparities in medication use: imperatives for managed care pharmacy

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of Managed Care & Specialty Pharmacy 2020-10-29

The COVID-19 pandemic and the social unrest pervading U.S. cities in response to the killings of George Floyd and other Black citizens at the hands of police are historically significant. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of Managed Care & Specialty Pharmacy 2016-08-31

Primary analysis calculated the impact of increasing the use of mirabegron from 4.5% to 5.3%, 7.1%, and 9.4% in years 1, 2, and 3, respectively, among oral pharmacological OAB treatments that included generic and branded antimuscarinics: oxybutynin, tolterodine, trospium, darifenacin, fesoterodine, and solifenacin. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Assessment for Alzheimer’s Disease Advancement Using Classification Models with Rules

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Applied Sciences 2023-11-08

Pre-diagnosis of common dementia conditions such as Alzheimer’s disease (AD) in the initial stages is crucial to help in early intervention, treatment plan design, disease management, and for providing quicker healthcare access. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Clinician-Identified Health Characteristics and Palliative Care Eligibility: Is Dementia Overlooked?

✓ Peer-reviewed alzhub usefulness score 36 out of 100. The American Journal of Managed Care 2025-11-01

Of 343 palliative care evaluations (for 322 unique patients), 38% were of patients who identified as African American/Black, 38% as White, 9% as Asian/Pacific Islander, and 15% as other races; 41% were of patients who identified as Hispanic/Latino (measured separately from race); 80% were of female patients; and the mean patient age was 88 years. 5 key findings →

Design: retrospective cohort Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Evidence-Based Mental Health 2012-06-22

Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder QUESTION Question: Is atypical antipsychotic use associated with incident diabetes or hyperlipidaemia in older people without schizophrenia or bipolar disorder? 1 key finding →

Participants: 75 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Characterize demographics, comorbidities and co‐medications in newly diagnosed United States (US) Alzheimer’s Disease patients using Medicare claims

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2023-12-01

Extensive understanding of a drug’s real‐world target population can inform generalizability of clinical trial results and highlight unaddressed risk. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The “American (cancer) patients first” plan to reduce drug prices—A critical assessment

✓ Peer-reviewed alzhub usefulness score 36 out of 100. American Journal of Hematology 2018-09-16

Serious concerns over the rising cost of cancer drugs in the United States1-3 are increasing,4-9 following a decade during which prices rose from an average of less than $10 000/year to more than $170 000/year in 2017.10 Despite the drug industry's wish to be “part of the solution,” the problem continues to worsen.6 Between 1995 and 2013, the launch price of cancer drugs increased by 10%-12% every year.11 According to a March 2018 report, the Average Wholesale Prices of drugs increased at unprecedented rates.12 A study by Gordon and colleagues showed a 25% average annual price increase of drugs already on the market, despite competition.13 Cancer drugs spending doubled since 2013 and is expected to double again by 2022.14 This suggests that health care is different from other industries where traditional free market forces are effective in lowering prices, and that other measures are needed. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Disparities in High-Risk Medication Use—Implications for Health Equity and Deprescribing Practices

✓ Peer-reviewed alzhub usefulness score 36 out of 100. JAMA Network Open 2025-04-14

Potentially inappropriate medication (PIM) use-defined as the use of high-risk medications that can increase the risk of adverse events such as physical, cognitive, and functional decline; delirium; hospitalizations; and mortality-remains a significant concern in older adults in the US.Numerous guidelines, including the American Geriatrics Society Beers Criteria 1 and the STOPP criteria, 2 define PIMs as medications for which the risk of adverse effects outweighs potential benefits or are inappropriate for specific populations or disease states, such dementia or kidney disease.PIM use may be particularly harmful in populations experiencing other health care disparities, as communities experiencing other consequences of health care inequity, including limited access to physicians or pharmacies, greater financial stress, and a higher comorbidity burden, may experience disproportionate effects from the adverse consequences of PIM use. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

P3‐429: Response to cholinesterase inhibitor medication at first renewal in a Canadian provincial drug coverage initiative: the British Columbia Alzheimer's Drug Therapy Initiative (BC ADTI) experience

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2010-07-01

Uncertainty surrounds cholinesterase inhibitor (ChEIs) effectiveness in mild to moderate Alzheimer Disease (AD). 2 key findings →

Participants: 2,678 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Modeling Early Detection and Geographic Variation in Health System Capacity for Alzheimer’s Disease‐Modifying Therapies

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2024-12-01

Widespread delivery of AD‐modifying therapies will require a combination of strategies to communicate the value of detection and treatment to patients, integrate PCPs into the detection and diagnosis pathway, and address capacity disparities across the United States. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Evaluation of four gamma-based methods for calculating confidence intervals for age-adjusted mortality rates when data are sparse

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Population Health Metrics 2022-05-07

The three modifications had comparable performance when the number of deaths was large relative to the denominator and the age distribution was as in the standard population. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Anger expression moderates the effects of neighborhood disadvantage on cognitive decline among African‐Americans in the Jackson Heart Study and Atherosclerosis Risk in Communities study

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2022-12-01

Dispositional inward anger expression may increase susceptibility to the detrimental impacts of neighborhood disadvantage on cognitive health. 2 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

American Indian Caregivers Policy

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Fourth World Journal 2025-08-13

American Indian governments located in a region west of the Cascade mountain range and the government of the state of Washington offer programs to serve the needs of a growing American Indian elder and disabled population through the services of individuals caring for family members and also individuals employed to provide care. 1 key finding →

Participants: 1,601 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed